At TopiVert, we believe that intervention in disease pathways at multiple points is more powerful than targeting just one.
Monotherapy vs combination therapy
Traditional drug research has focused on 'hitting' individual biological targets to arrest or modulate disease. While this has resulted in the introduction of many breakthrough drugs, single-target drugs are not able to fully correct complex disease conditions, such as inflammatory diseases, where a number of pathways can influence how the disease is manifest. As a result, single targets have, more often than not, failed to deliver significant advances over existing standard of care in recent decades.
To overcome this problem, many diseases such as cancer, diabetes and infectious disease, are treated using combination therapy, where several single target drugs are used in combination to attack the disease system on multiple fronts. However, this approach can be limited by the compounded cost of therapy and increased safety and tolerability burden when using several drugs together.
NSKIs are multiple-target therapeutics
At TopiVert, we create individual compounds that have a defined spectrum of activity against disease targets, rather than using combinations of different active compounds to achieve the desired biological effect. Specifically, we develop small molecules known as Non-Systemic Kinase Inhibitors (NSKIs) that are active against a selected number of kinases (P38, Src family kinases and Syk) involved in the signalling cascade in inflammatory diseases. This activity profile drives potent inhibitory effects in a wide range of cells playing pivotal roles in innate and adaptive immunity and has resulted in high efficacy in steroid-insensitive inflammatory conditions in vitro and in vivo.